… And Invests In Cancer Therapies | Chemical & Engineering News
Volume 93 Issue 18 | p. 17 | Concentrates
Issue Date: May 4, 2015

… And Invests In Cancer Therapies

Department: Business
Keywords: cancer, oncology, investment

Celgene will pay AstraZeneca $450 million to participate in development of MEDI4736, an anti-PD-L1 inhibitor for hematologic malignancies. The pact will focus on combining the AstraZeneca antibody with products in Celgene’s pipeline. Separately, Celgene has paid Northern Biologics, a biotech firm backed by Versant Ventures, $30 million for rights to license oncology antibodies in Northern’s pipeline and to acquire Northern. And Celgene has paid Agios Pharmaceuticals $10 million to expand an earlier pact to develop AG-881, a small molecule in development to treat brain cancer.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment